Francisco Cervantes

Summary

Country: Spain

Publications

  1. ncbi New and old treatment modalities in primary myelofibrosis
    Francisco Cervantes
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Cancer J 13:377-83. 2007
  2. ncbi Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia
    Jose Roman-Gomez
    Hematology Department, Reina Sofia Hospital, Avda Menendez Pidal s n 14004 Cordoba, Spain
    Haematologica 92:153-62. 2007
  3. ncbi Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis
    Alejandra Martínez-Trillos
    Hematology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Ann Hematol 93:797-802. 2014
  4. doi Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia
    Margherita Maffioli
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Leuk Res 35:1014-9. 2011
  5. ncbi Epigenetic regulation of PRAME gene in chronic myeloid leukemia
    Jose Roman-Gomez
    Hematology Department, Reina Sofia Hospital, Avda, Menendez Pidal s n, 14004, Cordoba, Spain
    Leuk Res 31:1521-8. 2007
  6. ncbi Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia
    Jose Roman-Gomez
    Hematology Department, Reina Sofia Hospital, Avda Menendez Pidal s n, 14004 Cordoba, Spain
    Leuk Res 32:487-90. 2008
  7. ncbi Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis
    Alberto Alvarez-Larran
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Ann Hematol 87:269-76. 2008
  8. ncbi Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden
    Eduardo Arellano-Rodrigo
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Am J Hematol 84:102-8. 2009
  9. doi Improving survival trends in primary myelofibrosis: an international study
    Francisco Cervantes
    Hospital Clinic, Institut d Investigacio Biomedica August Pi i Sunyer, University of Barcelona, Spain
    J Clin Oncol 30:2981-7. 2012
  10. doi Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
    Alberto Alvarez-Larran
    Hematology Department, Hospital del Mar, Barcelona, Spain
    Blood 116:1205-10; quiz 1387. 2010

Collaborators

Detail Information

Publications47

  1. ncbi New and old treatment modalities in primary myelofibrosis
    Francisco Cervantes
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Cancer J 13:377-83. 2007
    ..Newer immunomodulatory drugs, proteasome inhibitors, hypomethylating agents, and JAK2 inhibitors are currently being tested...
  2. ncbi Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia
    Jose Roman-Gomez
    Hematology Department, Reina Sofia Hospital, Avda Menendez Pidal s n 14004 Cordoba, Spain
    Haematologica 92:153-62. 2007
    ..To date, CTA genes have been shown to be expressed in a range of solid tumors via demethylation of their promoter CpG islands, but rarely in chronic myeloid leukemia (CML) or other hematologic malignancies...
  3. ncbi Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis
    Alejandra Martínez-Trillos
    Hematology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Ann Hematol 93:797-802. 2014
    ..Finally, no relationship was observed between the JAK2 46/1 haplotype and either the patients' prognostic score or survival. ..
  4. doi Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia
    Margherita Maffioli
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Leuk Res 35:1014-9. 2011
    ..Beside, the MDR1 haplotype 1236T-2677G-3435C was more frequently found in patients primarily resistant to imatinib...
  5. ncbi Epigenetic regulation of PRAME gene in chronic myeloid leukemia
    Jose Roman-Gomez
    Hematology Department, Reina Sofia Hospital, Avda, Menendez Pidal s n, 14004, Cordoba, Spain
    Leuk Res 31:1521-8. 2007
    ..0001). These results suggest that hypomethylation of PRAME up-regulates its expression in CML and might play a significant role in the progression of the disease...
  6. ncbi Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia
    Jose Roman-Gomez
    Hematology Department, Reina Sofia Hospital, Avda Menendez Pidal s n, 14004 Cordoba, Spain
    Leuk Res 32:487-90. 2008
    ..Furthermore, a more profound level of hypomethylation was observed among BC samples compared with CP samples. Our data suggest that repetitive DNA hypomethylation are closely associated with CML progression...
  7. ncbi Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis
    Alberto Alvarez-Larran
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Ann Hematol 87:269-76. 2008
    ..In conclusion, PMF patients have platelet, leukocyte, endothelial, and coagulation activation similar to that in PV and ET. CD11b overexpression and F1 + 2 are correlated with the presence of the JAK2 mutation...
  8. ncbi Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden
    Eduardo Arellano-Rodrigo
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Am J Hematol 84:102-8. 2009
    ....
  9. doi Improving survival trends in primary myelofibrosis: an international study
    Francisco Cervantes
    Hospital Clinic, Institut d Investigacio Biomedica August Pi i Sunyer, University of Barcelona, Spain
    J Clin Oncol 30:2981-7. 2012
    ..This study was aimed at ascertaining whether survival prolongation has actually occurred in PMF...
  10. doi Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
    Alberto Alvarez-Larran
    Hematology Department, Hospital del Mar, Barcelona, Spain
    Blood 116:1205-10; quiz 1387. 2010
    ..In the remaining low-risk patients, this therapy is not effective as primary prophylaxis of thrombosis, and observation may be an adequate option...
  11. doi Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
    Francisco Cervantes
    Hospital Clinic, Hematology Department, Institut d Investigacio Biomedica August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Blood 122:4047-53. 2013
    ..Additionally, patients randomized to ruxolitinib showed longer overall survival than those randomized to BAT (hazard ratio, 0.48; 95% CI, 0.28-0.85; log-rank test, P = .009)...
  12. pmc Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group
    Francisco Cervantes
    Hematology Department, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Haematologica 95:1317-24. 2010
    ..Despite the favorable results of imatinib front line in chronic-phase chronic myeloid leukemia there is room for improvement...
  13. doi Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia
    Eduardo Arellano-Rodrigo
    Department of Hemotherapy and Hemostasis, University of Barcelona, Barcelona, Spain
    Platelets 23:336-43. 2012
    ..The intensity of the agreement between the variables obtained by the two methods was moderate. These results support the possible value of MPC as surrogate parameter of platelet activation in ET...
  14. doi Myelofibrosis: an update on current pharmacotherapy and future directions
    Francisco Cervantes
    University of Barcelona, Hospital Clinic, Hematology Department, IDIBAPS, Villarroel 170, 08036 Barcelona, Spain
    Expert Opin Pharmacother 14:873-84. 2013
    ..Discovery of the JAK2 mutation has provided the basis for the introduction of a new class of drugs, the JAK inhibitors, in the treatment of MF...
  15. ncbi Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia
    Francisco Cervantes
    Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Br J Haematol 134:184-6. 2006
    ..006). None of the patients with appropriate serum erythropoietin levels responded. Treatment was usually well tolerated...
  16. doi Prognostication in primary myelofibrosis
    Francisco Cervantes
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Villarroel 170, Barcelona, Spain
    Curr Hematol Malig Rep 7:43-9. 2012
    ....
  17. ncbi Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status
    Eduardo Arellano-Rodrigo
    Hematology Department, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Haematologica 91:169-75. 2006
    ..The aim of the present study was to ascertain the role of platelet and leukocyte activation in the thrombosis of ET...
  18. ncbi Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging
    Francisco Cervantes
    Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Semin Oncol 32:395-402. 2005
    ..Such a staging system should be derived from a large population of patients, systematically collected from diagnosis without selection bias and followed over time...
  19. ncbi Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia
    Jose Roman-Gomez
    Hematology Department, Reina Sofia Hospital, Avda Menendez Pidal s n 14004, Cordoba, Spain
    Oncogene 24:7213-23. 2005
    ..005). The above results strongly suggest that activation of both sense and antisense transcriptions by aberrant promoter hypomethylation of the L1 elements plays a role in the progression and clinical behavior of the CML...
  20. doi Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
    Alejandra Martínez-Trillos
    Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Ann Hematol 89:1233-7. 2010
    ..HU is an effective and generally well-tolerated therapy for the hyperproliferative manifestations of MF. The accentuation of the anemia often induced by HU is usually manageable with concomitant treatment...
  21. ncbi Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients
    Juan Carlos Hernández-Boluda
    Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Leuk Lymphoma 46:717-22. 2005
    ..However, further studies are required to elucidate the possible prognostic importance of such biological findings in this disease...
  22. doi Management of essential thrombocythemia
    Francisco Cervantes
    Hematology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Hematology Am Soc Hematol Educ Program 2011:215-21. 2011
    ..Strict control of coexistent cardiovascular risk factors is mandatory for all patients. The role in ET therapy of new drugs such as pegylated IFN or the JAK2 inhibitors is currently under investigation...
  23. doi New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
    Francisco Cervantes
    Hematology Department, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Blood 113:2895-901. 2009
    ..JAK2V617F did not cluster with a specific risk group or affect survival...
  24. ncbi Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients
    Francisco Cervantes
    Haematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Br J Haematol 129:771-5. 2005
    ..001) and higher Hb at treatment start (P= 0.02). Toxicity was usually moderate, leading to treatment withdrawal in only two cases. Danazol is effective and well tolerated in a substantial proportion of MMM patients with anaemia...
  25. doi Advances in the understanding and management of primary myelofibrosis
    Francisco Cervantes
    Hematology Department, IDIBAPS, University of Barcelona, Barcelona, Spain
    Curr Opin Oncol 23:665-71. 2011
    ..We herein review the recent contributions to the understanding and management of PMF...
  26. ncbi Modern management of myelofibrosis
    Francisco Cervantes
    Haematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Br J Haematol 128:583-92. 2005
    ..The next candidates for the treatment of myelofibrosis are the thalidomide derivatives, the proteasome inhibitors, and vascular endothelial growth factor neutralizing antibodies...
  27. ncbi Idiopathic myelofibrosis associated with classic polyarteritis nodosa
    Mireia Camos
    Institute of Hematology and Oncology, Department of Hematology, Postgraduate School of Hematology Farreras Valenti, Hospital Clinic, Villarroel 170, University of Barcelona, Barcelona, 08036 Spain
    Leuk Lymphoma 44:539-41. 2003
    ..This case represents a new association between IM and an autoimmune disease and supports the hypothesis of an immune basis of IM in some patients...
  28. ncbi Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature
    Francisco Cervantes
    Haematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Br J Haematol 127:399-403. 2004
    ..In the multivariate analysis, serum erythropoietin level <125 U/l was found to be associated with a favourable response to rHuEPO, whereas lack of transfusional support had borderline significance...
  29. ncbi Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation
    Francisco Cervantes
    Haematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Br J Haematol 120:500-4. 2003
    ..Imatinib mesylate is effective and safe in chronic-phase CML patients with a previous history of intensive treatment...
  30. ncbi Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients
    Francisco Cervantes
    Haematology Department, Institute of Haematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Br J Haematol 118:786-90. 2002
    ..After a median the myelofibrotic transformation, three patients have died and four have not required treatment for MMM as yet...
  31. ncbi Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa
    Jose Roman-Gomez
    Hematology Department, Reina Sofia Hospital, Avda, Menendez Pidal s n, 14004 Cordoba, Spain
    J Clin Oncol 21:1472-9. 2003
    ..Although defective progenitor-stromal adhesion is a well-recognized feature of chronic myeloid leukemia (CML), the role of CDH13 abnormalities has not been evaluated in this disease...
  32. ncbi Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia
    Monica Pou
    Nephrology Department, Hospital Clinic, Barcelona, Spain
    Leuk Lymphoma 44:1239-41. 2003
    ..One year later the patient still has mild chronic renal failure and remains in chronic phase of CML on hydroxyurea treatment...
  33. ncbi Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and
    Ruben A Mesa
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:737-40. 2007
    ....
  34. ncbi Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 110:1092-7. 2007
    ....
  35. ncbi Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies
    Juan Carlos Hernández-Boluda
    Hematology and Medical Oncology Department, Hospital Clinico Universitario, Valencia, Spain
    Drugs Today (Barc) 38:601-13. 2002
    ..In this sense, it must be pointed out that imatinib has shown a remarkable activity in gastrointestinal stromal tumors...
  36. ncbi Idiopathic myelofibrosis associated with ulcerative colitis
    Eduardo Arellano-Rodrigo
    Institute of Hematology and Oncology, Department of Hematology, Postgraduate School of Hematology Farreras Valenti, Barcelona, Spain
    Leuk Lymphoma 43:1481-3. 2002
    ..The present case represents a new association of IM with an autoimmune disease and gives support to the hypothesis of a possible immune basis of some IM cases...
  37. ncbi Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    Stephen G O'Brien
    University of Newcastle, Newcastle, United Kingdom
    N Engl J Med 348:994-1004. 2003
    ..We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML...
  38. ncbi Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)
    Giovanni Barosi
    Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Blood 106:2849-53. 2005
    ..A histologic response was defined by changes in bone marrow fibrosis and cellularity grades. The combined use of these response definitions should help standardize the design and reporting of future clinical studies in MMM...
  39. ncbi Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 110:3540-6. 2007
    ..In summary, nilotinib is highly active and safe in patients with CML-CP after imatinib failure or intolerance. This clinical trial is registered at http://clinicaltrials.gov as ID no. NCT00109707...
  40. ncbi International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
    Ayalew Tefferi
    Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
    Blood 108:1497-503. 2006
    ..Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly...
  41. ncbi Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Brian J Druker
    Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    N Engl J Med 355:2408-17. 2006
    ..Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy...
  42. ncbi JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis
    Luz Martínez-Avilés
    Department of Pathology, Hospital del Mar, IMAS, Barcelona, Spain
    Haematologica 92:1717-8. 2007
    ..Initial hematologic data of these patients differ from those of V617F-positive patients, but there is no difference in thrombotic development and myelofibrotic transformation...
  43. pmc Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
    Stephanie J Lee
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:3500-7. 2008
    ..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT...
  44. ncbi Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options
    Ruben A Mesa
    Laboratory of Clinical Epidemiology, IRCCS Policlinico S Matteo, Pavia, Italy
    Best Pract Res Clin Haematol 19:495-517. 2006
    ..Modern therapy remains palliative but allogeneic stem cell transplantation might be curative to a selected group of patients. This chapter reviews both the old and the new therapy with regard to non-transplant treatment options for MMM...
  45. ncbi Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Blood 108:1809-20. 2006
    ..The importance of regular monitoring at experienced centers was highlighted...
  46. ncbi Portal hypertension secondary to myelofibrosis: a study of three cases
    Alberto Alvarez-Larran
    Hematology Department, Azienda Ospedaliero Universitaria di Careggi, Firenze, Italy
    Am J Gastroenterol 100:2355-8. 2005
    ..In patients with idiopathic myelofibrosis (IM), portal hypertension (PHT) without thrombosis of the hepatic or splenoportal veins is infrequent...
  47. ncbi Late response to donor lymphocyte infusions in patients with chronic myeloid leukemia relapsing after allogeneic stem cell transplantation
    Marta Gomez
    Haematologica 87:1003-5. 2002
    ..The median time (range) in months to achieve a hematologic, cytogenetic and molecular remission was 2 (1-2), 5 (1-42) and 5 the median response duration is 16 months (range 1-36), and no patient shows evidence of relapse...